Introduction Sodium-glucose co-transporters 2 (SGLT-2) inhibitors are a relatively novel
class of oral medications for the treatment of Type 2 Diabetes Mellitus, which lower plasma …

Euglycemic diabetic ketoacidosis (euDKA) related to sodium-glucose cotransporter 2
inhibitor (SGLT2-I), despite being reported as consistent, though infrequent, adverse effect in …

Background: SGLT-2 inhibitors are a novel class of antidiabetic drugs, recently approved for
the treatment of patients with T2DM. Their cardioprotective and renoprotective action, along …

Study Objective Currently only minimal information is available regarding risk factors for the
development of sodium glucose cotransporter‐2 inhibitor (SGLT 2i)‐related diabetic …

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are emerging as an important therapy
not only for type 2 diabetes (T2DM), but also for heart disease and kidney disease. As these …

Sodium–glucose co-transporter type 2 (SGLT2) inhibitors are a new class of oral anti-
diabetic agents with a unique, insulin-independent mode of action. In patients with diabetes …

Abstract Sodium-glucose cotransporter-2 (SGLT2) inhibitors are drugs designed to lower
plasma glucose concentration by inhibiting Na+-glucose–coupled transport in the proximal …

Background Sodium-glucose cotransporter-2 (SGLT2) inhibitors (SGLT2i) showed benefits
in type 1 diabetes mellitus (T1DM), but the risk of diabetic ketoacidosis (DKA) limits their use …

Abstract Purpose of Review The aim of this review is to summarize existing research
investigating the use of sodium glucose cotransporter-2 (SGLT2) inhibitors in patients with …

Insights Into the Recognition and Management of SGLT2-Inhibitor-Associated Ketoacidosis: It's
Not Just Euglycemic Diabetic Ketoacidosis - ScienceDirect Skip to main contentSkip to article …